【学会発表】IQVIAジャパンが日本臨床疫学会第3回年次学術大会で演題発表しました

10 02, 2019

IQVIAジャパン は、日本臨床疫学会第3回年次学術大会で、「Oncology Dynamics: A DB survey across 8 countries for evaluating NSCLC treatment options related to PD-1/PD-L1」の演題について以下の要領で成果発表しました。

【会議名および開催概要】

大会名:日本臨床疫学会第3回年次学術大会
開催期間・場所:2019年9月28日(土)-29日(日), パピヨン24
大会ホームページ:http://jsce2019.umin.ne.jp/index.html

[発表内容1]

  • 演題:Oncology Dynamics: A DB survey across 8 countries for evaluating NSCLC treatment options related to PD-1/PD-L1
  • 番号:P6-6
  • 演者:Seok-Won Kim
  • 内容Introduction: Non-Small Cell Lung Cancer (NSCLC) is regarded as a disease with genetic mutation. PD-1/PD-L1 inhibitors are effective in cancer treatment in Japan. The PD-1/PD-L1 pathway is an important regulator in tumor growth in NSCLC and PD-1/PD-L1 inhibitors have revolutionised the treatment of NSCLC. Some PD-1/PD-L1 treatments require an authority of approved test confirming PD-1 expression. There is a lack of published data comparing current real-world testing rates, and PD-1/PD-L1 antibody use in different countries.
    Methods: PD-L1 immunohistochemistry assay is collected within IQVIA Oncology Dynamics, a syndicated cross-sectional survey collecting anonymized patient-level data in France, Germany, Spain, Italy, UK China, Korea, and Japan from January to December 2017.
    Results: 17,886 surveyed NSCLC patients, 32.3% were examined for PD-L1 expression across eight countries. Specifically, the ratio in each country was 35.4% in Japan, 35.5% Korea, 2.4% China, 34.2% France, 67.8% Germany, 54.7% United Kingdom, 21.6% Italy, and 38.3% in Spain. Additionally, 61.7% of NSCLC metastatic patients with PD-L1 expression were prescribed anti-PD-1 and anti-PDL-1 antibodies: 52.1% Japan, 26.7% Korea, China 25.0%, 63.5% Germany, 61.1% Spain, 48.3% France, 74.1% Great Britain, 71.2% Italy. Among patients prescribed anti-PD-1 and anti-PDL-1 antibodies (n=1,339), 62.4% received Pembrolizumab, 36.0% Nivolumab, 1.1% Atezolizumab, 0.3% Avelumab and 0.3% Durvalumab.
    Conclusion: This survey demonstrates a difference across eight countries in PD-1 expression testing and use of anti-PD-1 and anti-PD-L1 antibodies. The significance of PD-L1 expression remains to be defined within this patient segment as testing rates for expression remain minimal or absent in some countries. Further analysis is required to understand the time to PD-1/PD-L1 expression testing and differences in patient profiles between those treated with standard of care vs. anti-PD-1/PD-L1 treatments.